Total Company Value: Advanced Biomed Inc (ADVB)

Brandmark of Advanced Biomed (ADVB)

Taiwanese oncology diagnostics developer Advanced Biomed Inc (ADVB) is mitigating geopolitical risks by relocating its operational processes and patents to the US. The business focuses on developing microfluidic systems for AI-powered automated blood analysis. This price chart reflects an Enterprise Value of 4.53, supporting the brand's ambitions to implement ultra-precise "liquid biopsy" methods for the earliest possible detection of pathologies.

ADVB Advanced Biomed Inc: Enterprise Value in the range 11/23/2025 - 10/27/2026

ADVB (Advanced Biomed): analytical breakdowns and indicator data

- price and consensus price forecast:
Share Price Advanced Biomed Inc.|ADVB - Consensus Target
- market capitalization data:
Market Value Advanced Biomed|ADVB - Enterprise Value
- book capitalization data:
Net Assets per Single Share Advanced Biomed|ADVB - Book Capitalization|Market Cap to Net Assets Ratio advanbiomed.com|ADVB - Company Total Assets
- debt and liquidity data:
Total Debt to Capital Advanced Biomed Inc|ADVB - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio Advanced Biomed Inc.|ADVB - Company Aggregate Debts|Debt to Book Value Advanced Biomed
Fundamental company valuation:ADVB (Advanced Biomed Inc)
Manufactured products of Advanced Biomed Inc

Enterprise Value (EV) represents the total buyout price of a business, combining market capitalization and net debt. The charted value of the enterprise reflects the actual cost of acquiring the assets of Advanced Biomed Inc (ADVB) while accounting for liabilities. For liquid biopsy systems, this metric determines the capitalization efficiency of early cancer detection technologies. Analyzing the trend helps avoid overpaying at historical peaks. This indicator confirms the fundamental stability of the company.

Direct competitors

ONC - Business Value|HALO - Real Price to Acquire Entire Company|RVMD - Total Company Value|Ascentage Pharma Group (AAPG) - Enterprise Value|cgoncology.com (CGON) - Total Company Value|Enterprise Value URGN|Real Price to Acquire Entire Company Bicara Therapeutics Inc|Enterprise Value PSNL|Enterprise Value ERAS (Erasca Oncology)|DCTH - Total Company Value|Business Value ymabs.com YMAB|AURA: Enterprise Value|CADL - Real Price to Acquire Entire Company|Enterprise Value ARAY|SLS (SELLAS Life Sciences Group) - Total Enterprise Value|ACTU - Total Company Value|Value Adjusted for Debt and Cash citiusonc.com (CTOR)|TuHURA Biosciences, Inc. (HURA) - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash Protara Therapeutics Inc (TARA)|Fate Therapeutics Corp - Enterprise Value|WHWK - Real Price to Acquire Entire Company|TScan - Real Price to Acquire Entire Company|CSBR: Enterprise Value|Total Company Value xbiotech.com XBIT|CEL-SCI (CVM) - Value Adjusted for Debt and Cash|Enterprise Value OSTX (OS Therapies Inc)|Total Enterprise Value radiopharmtheranostics.com|Enterprise Value ARTV|Enterprise Value adlainortye.com (ANL)|VERU - Enterprise Value|TPST - Business Value|XLO - Real Price to Acquire Entire Company|RENB - Total Company Value|MURA: Enterprise Value|KAPA (Kairos Pharma) - Enterprise Value|Total Company Value OnKure Therapeutics, Inc. (OKUR)|Business Value CytoMed|Enterprise Value CRIS (Curis, Inc.)|Real Price to Acquire Entire Company apollomicsinc.com (APLM)|THAR: Enterprise Value|Total Enterprise Value genprex.com GNPX|Calidi Bio (CLDI) - Enterprise Value|sunshinebiopharma.com (SBFM) - Business Value|Real Price to Acquire Entire Company xeneticbio.com XBIO|Salarius Pharma (SLRX) - Value Adjusted for Debt and Cash|Enterprise Value Purple Biotech|Total Company Value AON|BGNE (BeiGene) - Enterprise Value|Company Buyout Price CKPT (Checkpoint Therapeutics Inc.)|ELEV: Total Company Value|iCAD Inc. - Total Enterprise Value|IKNA: Total Company Value|NTBL - Real Price to Acquire Entire Company|Enterprise Value VIRX|MorphoSys Inc (MOR) - Total Enterprise Value|Enterprise Value NAYA Bio (NAYA)|Business Value Ascentage (AAPGV)